- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What We’re Reading: FDA Approves Expanded Use of Keytruda; Menthol Cigarette Ban; Diagnostic Errors in US Hospitals
Merck’s pembrolizumab (Keytruda) gains expanded approval for advanced cervical cancer; delay of final rules banning menthol cigarettes and flavored cigars; high rates of diagnostic errors lead to harm and deaths, study finds.
FDA Approves Expanded Use of Pembrolizumab for Patients With Newly Diagnosed Advanced Cervical Cancer
The FDA has granted approval for the expanded use of Merck's immunotherapy drug pembrolizumab (Keytruda), in combination with chemoradiotherapy, to be used for the treatment of patients newly diagnosed with a type of advanced cervical cancer who have not received prior surgery, radiation, or systemic therapy, according to Reuters. This makes pembrolizumab the first anti–PD-1–based immunotherapy approved in the US for the first-line treatment of this type of cervical cancer, marking a significant advancement in cancer treatment options. The drug demonstrated efficacy in reducing the risk of cancer progression or death by 41% in a late-stage trial involving 1060 patients with advanced cervical cancer.
Biden Administration Urged to Publish Rules Banning Menthol Cigarettes, Flavored Cigars
A group of Senate Democrats and advocacy groups have called on the Biden administration to promptly publish 2 final rules banning menthol-flavored cigarettes and all flavored cigars, according to The Hill. The lawmakers emphasized the urgency of these regulations, citing concerns that delays could lead to increased addiction and health risks. The proposed ban on menthol cigarettes was initially introduced by the Biden administration in 2022, and the final version, initially expected in August, faced delays, with the White House pushing the ban's implementation to at least March 2024. The senators and supporting groups are urging the administration to reject arguments they say are driven by the tobacco industry and instead prioritize public health.
Study Reveals High Rates of Diagnostic Errors Leading to Harm and Deaths in US Hospitals
A recent study highlighted the prevalence of diagnostic errors in US hospitals, reporting that nearly 1 in 4 hospital patients who died or were transferred to intensive care had experienced a diagnostic error, according to NBC News. The study found approximately 18% of misdiagnosed patients suffered harm or died. Furthermore, racial and gender disparities were evident, with women and ethnic minorities being 20% to 30% more likely than White men to experience misdiagnosis. The study also emphasized the urgent public health problem of diagnostic errors, estimating that 795,000 patients a year in the US suffer permanent disability or death due to misdiagnosis.
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
